Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18162326 | 0.83 | RECQL (0.36) | — | |
| SCHEMBL22903026 | 0.79 | LMNA (0.38) | PRSS1PRSS2PRSS3LMNA | |
| SCHEMBL18739244 | 0.75 | CYP3A4 (0.33) | PRSS1PRSS2PRSS3LMNA | |
| SCHEMBL19287538 | 0.67 | CA1 (0.33) | — | |
| SCHEMBL16694596 | 0.66 | TSHR (0.52) | PRSS1PRSS2PRSS3LMNA | |
| SCHEMBL30630486 | 0.66 | PRSS1 (0.40) | PRSS1PRSS2PRSS3LMNA | |
| SCHEMBL29479942 | 0.66 | PRSS1 (0.40) | PRSS1PRSS2PRSS3LMNA | |
| SCHEMBL28069731 | 0.66 | CYP3A4 (0.46) | PRSS1PRSS2PRSS3LMNA | |
| SCHEMBL28272444 | 0.66 | CYP3A4 (0.46) | PRSS1PRSS2PRSS3LMNA | |
| SCHEMBL16759507 | 0.66 | CYP3A4 (0.46) | PRSS1PRSS2PRSS3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550704-B2 | Method for synthesizing radiopharmaceuticals using a cartridge | FUTURECHEM CO., LTD. (KR) | 2017-01-24 | — | — | US | disclosed |
| US-20150232392-A1 | METHOD FOR SYNTHESIZING RADIOPHARMACEUTICALS USING A CARTRIDGE | FUTURECHEM CO., LTD. (KR) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232392-A1 | METHOD FOR SYNTHESIZING RADIOPHARMACEUTICALS USING A CARTRIDGE | ADCYAP1R1, PAICS, SSTR5 | PRSS1 3668/4885PRSS2 3121/4885PRSS3 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.